- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A critical appraisal
- Systematic review with meta-analysis: Association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation
- Association of antenatal steroid and risk of retinopathy of prematurity: A systematic review and meta-analysis
- Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: A randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)
- Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British society for rheumatology biologics register for rheumatoid arthritis
- Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: An open-label multicenter study
- Laxative use and clinical correlates in hospitalized patients with obsessive-compulsive disorder: A retrospective descriptive study
- Cancer-salient messaging for Human Papillomavirus vaccine uptake: A randomized controlled trial
- A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
- Single-dose comparative pharmacokinetics of two formulations of lenalidomide 25 mg in healthy subjects: A randomized crossover study
- Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS)
- Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
- Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial
- Cabozantinib vs sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- Adjuvant zoledronic acid reduces fractures in breast cancer patients: An AZURE (BIG 01/04) study
Feed Sources
